BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$413.26+1.97 (+0.48%)
Close on Nov 17, 2026Market cap $46.99BP/E 73.9Yield –
BeOne Medicines total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
BeOne Medicines's total debt was $1.14B at Jun 30, 2026. For fiscal 2025 it was $1.03B, down 45.0% from the year before. The highest annual figure on record is $1.87B in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | -45.0% |
| FY2024 | Dec 31, 2024 | $1.87B | +111.0% |
| FY2023 | Dec 31, 2023 | $885.98M | +64.6% |
| FY2022 | Dec 31, 2022 | $538.12M | -14.5% |
| FY2021 | Dec 31, 2021 | $629.68M | -26.2% |
| FY2020 | Dec 31, 2020 | $853.67M | +924.7% |
| FY2019 | Dec 31, 2019 | $83.31M | +68.3% |
| FY2018 | Dec 31, 2018 | $49.51M | +168.4% |
| FY2017 | Dec 31, 2017 | $18.44M | +6.7% |
| FY2016 | Dec 31, 2016 | $17.28M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.14B | +19.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.09B | +17.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.03B | -45.0% |
| Q3 FY2025 | Sep 30, 2025 | $813.30M | -22.6% |
| Q2 FY2025 | Jun 30, 2025 | $954.49M | -8.0% |
| Q1 FY2025 | Mar 31, 2025 | $923.63M | -10.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.87B | +111.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.05B | +98.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.04B | +65.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.03B | +110.2% |
| Q4 FY2023 | Dec 31, 2023 | $885.98M | +64.6% |
| Q3 FY2023 | Sep 30, 2023 | $531.05M | -18.2% |
| Q2 FY2023 | Jun 30, 2023 | $628.48M | +11.1% |
| Q1 FY2023 | Mar 31, 2023 | $488.11M | -19.9% |
| Q4 FY2022 | Dec 31, 2022 | $538.12M | -14.5% |
| Q3 FY2022 | Sep 30, 2022 | $649.33M | +0.9% |
| Q2 FY2022 | Jun 30, 2022 | $565.94M | -10.1% |
| Q1 FY2022 | Mar 31, 2022 | $608.99M | +1.8% |
| Q4 FY2021 | Dec 31, 2021 | $629.68M | -26.2% |
| Q3 FY2021 | Sep 30, 2021 | $643.28M | +218.8% |
| Q2 FY2021 | Jun 30, 2021 | $629.66M | +299.7% |
| Q1 FY2021 | Mar 31, 2021 | $598.06M | +541.6% |
| Q4 FY2020 | Dec 31, 2020 | $853.67M | +924.7% |
| Q3 FY2020 | Sep 30, 2020 | $201.77M | +92.3% |
| Q2 FY2020 | Jun 30, 2020 | $157.55M | +69.0% |
| Q1 FY2020 | Mar 31, 2020 | $93.21M | +7.9% |
| Q4 FY2019 | Dec 31, 2019 | $83.31M | +68.3% |
| Q3 FY2019 | Sep 30, 2019 | $104.93M | +111.7% |
| Q2 FY2019 | Jun 30, 2019 | $93.23M | +54.0% |
| Q1 FY2019 | Mar 31, 2019 | $86.42M | +351.8% |
| Q4 FY2018 | Dec 31, 2018 | $49.51M | +168.4% |
| Q3 FY2018 | Sep 30, 2018 | $49.56M | +449.6% |
| Q2 FY2018 | Jun 30, 2018 | $60.53M | +2350.8% |
| Q1 FY2018 | Mar 31, 2018 | $19.13M | +10.7% |
| Q4 FY2017 | Dec 31, 2017 | $18.44M | – |
| Q3 FY2017 | Sep 30, 2017 | $9.02M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.47M | – |
| Q4 FY2016 | Dec 31, 2016 | $17.28M | – |
See a number that looks wrong?